{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T14:46:49Z","timestamp":1778770009673,"version":"3.51.4"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K08 DK118120"],"award-info":[{"award-number":["K08 DK118120"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UL1 TR000135"],"award-info":[{"award-number":["UL1 TR000135"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000871","name":"Mayo Clinic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.xkme.2023.100626","type":"journal-article","created":{"date-parts":[[2023,3,13]],"date-time":"2023-03-13T03:42:48Z","timestamp":1678678968000},"page":"100626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immune Checkpoint Inhibitor\u2013Associated Sarcoidosis Reaction in the Kidney: Case Report"],"prefix":"10.1016","volume":"5","author":[{"given":"Mariam","family":"Charkviani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3700-4537","authenticated-orcid":false,"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.xkme.2023.100626_bib1","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.xkme.2023.100626_bib2","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/j.ekir.2020.04.018","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.xkme.2023.100626_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.xkme.2023.100626_bib4","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.kint.2016.04.008","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","journal-title":"Kidney Int"},{"issue":"10","key":"10.1016\/j.xkme.2023.100626_bib5","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","journal-title":"J\u00a0Immunother Cancer"},{"issue":"6","key":"10.1016\/j.xkme.2023.100626_bib6","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.xkme.2021.08.008","article-title":"Immune checkpoint inhibitors and kidney toxicity: advances in diagnosis and management","volume":"3","author":"Seethapathy","year":"2021","journal-title":"Kidney Med"},{"issue":"4","key":"10.1016\/j.xkme.2023.100626_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.ajkd.2017.04.026","article-title":"Nephrotic syndrome with cancer immunotherapies: a report of 2 cases","volume":"70","author":"Kitchlu","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.xkme.2023.100626_bib8","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.ekir.2020.05.027","article-title":"Immune check point inhibitor-associated endothelialitis","volume":"5","author":"Bobart","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"6","key":"10.1016\/j.xkme.2023.100626_bib9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1053\/j.ajkd.2019.04.016","article-title":"Renal vasculitis and pauci-immune glomerulonephritis associated with immune checkpoint inhibitors","volume":"74","author":"Gallan","year":"2019","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1016\/j.xkme.2023.100626_bib10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1681\/ASN.2018050488","article-title":"Nephrotoxicity of cancer immunotherapies: past, present and future","volume":"29","author":"Perazella","year":"2018","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.xkme.2023.100626_bib11","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/j.jtho.2018.04.031","article-title":"Sarcoidosis-like reactions induced by checkpoint inhibitors","volume":"13","author":"Gkiozos","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.xkme.2023.100626_bib12","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.ejca.2021.05.041","article-title":"Immune checkpoint inhibitor-associated sarcoidosis: a usually benign disease that does not require immunotherapy discontinuation","volume":"158","author":"Chanson","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.xkme.2023.100626_bib13","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.2215\/CJN.02340219","article-title":"AKI in patients receiving immune checkpoint inhibitors","volume":"14","author":"Perazella","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.xkme.2023.100626_bib14","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.2217\/imt-2017-0128","article-title":"Sarcoidosis, malignancy and immune checkpoint blockade","volume":"9","author":"Gaughan","year":"2017","journal-title":"Immunotherapy"},{"issue":"9923","key":"10.1016\/j.xkme.2023.100626_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(13)60680-7","volume":"383","author":"Valeyre","year":"2014","journal-title":"Sarcoidosis. Lancet"},{"issue":"36","key":"10.1016\/j.xkme.2023.100626_bib16","first-page":"4073","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol","volume":"39","author":"Schneider","year":"2021","journal-title":"20"},{"issue":"4","key":"10.1016\/j.xkme.2023.100626_bib17","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.ekir.2021.01.013","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"5","key":"10.1016\/j.xkme.2023.100626_bib18","doi-asserted-by":"crossref","first-page":"799","DOI":"10.34067\/KID.0003962021","article-title":"Is rechallenge appropriate in patients that develop immune checkpoint inhibitor-associated AKI?: PRO","volume":"3","author":"Herrmann","year":"2022","journal-title":"Kidney360"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523000353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059523000353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:25:29Z","timestamp":1762910729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059523000353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2590059523000353"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100626","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune Checkpoint Inhibitor\u2013Associated Sarcoidosis Reaction in the Kidney: Case Report","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2023.100626","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100626"}}